Anlon Healthcare shares make a tepid debut. Should IPO investors wait or sell?
Anlon Healthcares shares debuted with a modest 1% premium amid volatile pharma markets, despite a strong 7.12x IPO subscription driven by retail investors. The specialized API manufacturer showed robust financial growth, with revenue up 81% in FY25 and expanding profit margins. While niche products and global approvals boost prospects, risks include limited operating history and regulatory challenges. Analysts consider the IPO fully priced.
Anlon Healthcares shares debuted with a modest 1% premium amid volatile pharma markets, despite a strong 7.12x IPO subscription driven by retail investors. The specialized API manufacturer showed robust financial growth, with revenue up 81% in FY25 and expanding profit margins. While niche products and global approvals boost prospects, risks include limited operating history and regulatory challenges. Analysts consider the IPO fully priced.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
